
Clinical TrialNov 20, 2026, 08:31 AM
Alamar Biosciences Assay Shows Promise for CTE Blood Test in JAMA Study
AI Summary
Alamar Biosciences, Inc. announced new research published in JAMA demonstrating the potential of its NULISAqpcr™ eMTBR-tau assay to detect chronic traumatic encephalopathy (CTE) pathology in living patients via a blood test. The study found higher blood levels of eMTBR-tau in former football players with advanced CTE, with levels correlating to brain pathology. While promising, researchers emphasize the need for further validation in larger cohorts, and the test is not yet a diagnostic tool for clinical use. The findings could enable new research into CTE progression and treatment.
Key Highlights
- Alamar Biosciences' NULISAqpcr™ eMTBR-tau assay used in JAMA study to evaluate blood test for CTE detection.
- Study found higher blood eMTBR-tau levels in former football players with advanced CTE.
- eMTBR-tau levels correlated with the amount of tau tangle pathology in the brain.
- The assay may help differentiate CTE from Alzheimer's disease when used with p-tau217.
- Researchers highlight the need for validation in larger, diverse cohorts.
- The test is currently not a diagnostic tool and not available for clinical use.
Price Impact
More from ALMR